SCHEMBL2945976

SCHEMBL2945976

Cc1ccccc1-c1ccc2c(-c3ccccc3C)nncc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 9/20 0.60
KIT P10721 3/20 0.60
MAPK9 P45984 1/20 0.60
MAPK10 P53779 1/20 0.60
CYP3A4 P08684 3/20 0.54
LCK P06239 3/20 0.51
KDR P35968 3/20 0.51
TRPA1 O75762 1/20 0.49
JAK3 P52333 1/20 0.47
CTSD P07339 1/20 0.46
BACE1 P56817 1/20 0.46
NR3C1 P04150 1/20 0.41
PGR P06401 1/20 0.41
ALOX5AP P20292 1/20 0.40
FEN1 P39748 1/20 0.40
CYP1A2 P05177 2/20 0.39
CYP2D6 P10635 2/20 0.39
TSHR P16473 2/20 0.39
CYP2C19 P33261 2/20 0.39
CLK4 Q9HAZ1 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2945468 0.84 MAPK14 (0.48) MAPK14KITMAPK9MAPK10CYP3A4
SCHEMBL2955979 0.84 TRPA1 (0.48) MAPK14KITMAPK9MAPK10CYP3A4
SCHEMBL2945585 0.84 MAPK14 (0.48) MAPK14KITMAPK9MAPK10CYP3A4
SCHEMBL2948437 0.83 MAPK14 (0.70) MAPK14KITMAPK9MAPK10CYP3A4
SCHEMBL29941671 0.82 MAPK14 (0.48) MAPK14KITMAPK9MAPK10CYP3A4
SCHEMBL2944568 0.80 MAPK14 (0.48) MAPK14KITMAPK9MAPK10CYP3A4
SCHEMBL601354 0.79 MAPK14 (0.47) MAPK14KITMAPK9MAPK10CYP3A4
SCHEMBL1406087 0.79 MAPK14 (0.73) MAPK14KITMAPK9MAPK10CYP3A4
SCHEMBL2956155 0.78 MAPK14 (0.55) MAPK14KITMAPK9MAPK10CYP3A4
SCHEMBL2953214 0.77 MAPK14 (1.00) MAPK14KITMAPK9MAPK10CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1856058-B1 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2014-09-03 EP claimed
US-7759337-B2 Phthalazine compounds and methods of use AMGEN INC. (US) 2010-07-20 US claimed
EP-1856058-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-11-21 EP claimed
WO-2006094187-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2006-09-08 WO claimed
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use AMGEN INC. (US) 2006-09-07 US claimed
EP-1856058-B1 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2014-09-03 EP disclosed
US-7759337-B2 Phthalazine compounds and methods of use AMGEN INC. (US) 2010-07-20 US disclosed
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use AMGEN INC. (US) 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use DAPK2, CDK2, DAPK1 MAPK14 293/4885KIT 1977/4885MAPK9 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.